China's 15th Five-Year Plan triggers Hong Kong biotech ETF surge of over 4%
On September 21, 2025, Hong Kong's Hang Seng Biotech ETF surged over 4% for a third consecutive day, following the September 20 announcement by ten Chinese government departments of the "15th Five-Year Plan" for the medical and health industry. The plan targets China's original innovative drugs to account for at least 25% of global innovative drugs by 2030, with an annual growth rate of no less than 20%. The rally continued through September 23, with the sector rising despite a broader market decline, driven by AI drug R&D trends and industry transformation from quantity to quality competition.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Reporting timeline
Hong Kong Biotech Stocks Rise on Multiple Catalysts; AI Drug R&D Among Key Trends
On September 23, Hong Kong's three major indices declined, but the biotech sector rose on multiple positive catalysts. The Hang Seng Bio-Tech ETF (159892) saw active trading, with turnover exceeding 200 million yuan by 9:50 AM, ranking first in its category. Stocks showed mixed performance, with 3SBio, Jingtai Holdings, and BeiGene leading gains, while Deshi, Zai Lab, and WuXi XDC declined. Huaxin Securities identified key trends in innovative drugs: AI is accelerating drug R&D as multinational companies shift from licensing AI drugs to reshaping drug development infrastructure, boosting wet-lab validation demand; mRNA cancer vaccines from Moderna and Merck show positive results in melanoma adjuvant therapy, though more clinical data support is needed; domestic innovative drug companies show diverging growth, with firms like Hutchison China MediTech and Innovent Biologics maintaining high growth and strong overseas expansion; CDMO orders are growing due to global blockbuster drugs like tirzepatide and Foundayo; and the TYK2 target market potential is gradually being realized, with Chinese companies actively positioning for autoimmune drug exports. The ETF tracks the Hang Seng Bio-Tech Index, which includes companies listed under HKEX Chapter 18A, covering pre-revenue biotech firms and CXO leaders.
Hong Kong Biotech ETF Rises as Sector Shifts from Quantity to Quality Competition
As of 09:58 on September 23, 2026, the Boshi Hong Kong Biotech ETF (520690) tracked the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index (HSSCPB), which rose 1.18%. Constituent stocks including Kangfang Biotech (+4.12%), CanSino Biologics (+3.74%), and 3SBio (+3.34%) led gains. The article reports that China's innovative drug industry is transitioning from a focus on pipeline quantity to quality competition, driven by regulatory reforms encouraging clinical value and companies voluntarily terminating undifferentiated projects. Xiangcai Securities stated that China's innovative drugs have entered a new phase of globalization, achieving breakthroughs in ADC and bispecific antibodies, moving from follow-on to original innovation. Guojin Securities noted that domestic innovative drug financing is improving, BD transaction activity is rising, and preclinical CRO orders are ample, with the sector entering a volume-price recovery channel. The ETF's top ten holdings include Innovent Biologics, BeiGene, CSPC Pharmaceutical Group, and others, comprising 69.08% of the portfolio.
Read sourceHong Kong Biotech ETF Surges 4% for Third Day on China's New Healthcare Plan
On September 21, the Hang Seng Index rose 0.93% to 24,980.48 points, with the biotech sector gaining attention. The Hang Seng Biotech ETF (Guotai) tracking the index surged 4%, marking a three-day winning streak amid increased trading activity. The rally follows a September 20 announcement by ten Chinese government departments of the '15th Five-Year Plan' for the medical and health industry, which sets targets for China's original innovative drugs to account for at least 25% of global innovative drugs by 2030, with an annual growth rate of no less than 20% for the innovative drug industry. The plan also mandates AI integration across the entire drug discovery and regulatory chain, shifting policy from 'manufacturing upgrade' to 'global innovation leadership'. The article notes that the biotech sector benefits from high growth potential, an aging population, and expanding healthcare demand. The ETF, which supports T+0 trading, tracks the top 30 Hong Kong-listed biotech companies eligible for Stock Connect, including major holdings such as Innovent Biologics, BeiGene, WuXi Biologics, and WuXi AppTec. The article includes a risk disclaimer stating that the information does not constitute investment advice.
Read sourceShow 3 older updatesHide older updates
Hang Seng Biotech ETF Guotai Tracks Index Up Over 4%, Supports T+0 Trading
On September 21, the Hong Kong stock market rose, with the Hang Seng Index up 0.57%. The biotech sector was notably active, with the Hang Seng Biotech ETF Guotai's underlying index surging over 4%. This ETF supports T+0 trading, offering investors a flexible on-exchange tool. The fund tracks the Hang Seng Biotech Index (HSBIO), which reflects the performance of the 30 largest Hong Kong-listed biotech companies eligible for Stock Connect, including those listed under Chapter 18A. The article notes that the sector benefits from China's improving innovative drug R&D capabilities and a wave of overseas commercialization. It highlights that the ETF's top ten holdings include leading firms such as Innovent Biologics, BeiGene, WuXi Biologics, and WuXi AppTec. The article positions the ETF as an efficient tool for investing in Hong Kong's innovative drug and biotech industry chain, citing its T+0 flexibility and the high-growth nature of its underlying assets. A risk disclaimer is included, stating that the information does not constitute investment advice and that past performance does not guarantee future results.
Read sourceHong Kong Biotech ETF Surges 4.5% as Sector Attracts Investment Amid Market Recovery
On September 21, Hong Kong stock market sentiment improved, with the Hang Seng Index rising 0.61% to 24,901.21. The Hang Seng Bio-Tech ETF (520930), which tracks the Hang Seng Bio-Tech Index, surged 4.5%, demonstrating strong sector elasticity and investment appeal as the market stabilizes. The ETF, which supports T+0 trading, offers investors a convenient channel to invest in Hong Kong-listed biotech stocks. The underlying index has risen for three consecutive days, showing signs of bottoming and consolidation. The Hang Seng Bio-Tech Index reflects the performance of the 30 largest Hong Kong-listed biotech companies eligible for Stock Connect, including those listed under Chapter 18A. The article states that the global biotech industry is driven by innovative drug commercialization and a new technology cycle. With improved Hong Kong market liquidity, biotech companies with high R&D barriers and long-term growth potential are expected to undergo a systematic valuation reset, highlighting medium-to-long-term investment value. The ETF's top ten holdings include Innovent Biologics, BeiGene, WuXi Biologics, WuXi AppTec, Akeso, CSPC Pharmaceutical, Sino Biopharmaceutical, Hansoh Pharma, 3SBio, and Kelun-Biotech.
Read sourceHong Kong Biotech ETF Surges Over 4% as Innovation Drug Sector Rebounds, Index Shows
As of press time, the Hang Seng Index stood at 24,835.28, up 0.34%. The Hang Seng Biotech ETF (Guotai) tracking index surged over 4%, supporting T+0 trading, and has risen for three consecutive days, showing strong rebound resilience. The article argues that the biotech sector currently offers significant investment value, driven by policy support and technological breakthroughs in innovative drug R&D, high-end medical devices, and the biopharmaceutical industry chain. Leading companies are expected to achieve breakthroughs in niche areas due to their technological advantages and R&D investment, with internationalization of innovative drugs and domestic substitution of high-end medical devices as core growth drivers. The Hang Seng Biotech ETF tracks the Hang Seng Biotech Index, which reflects the performance of the 30 largest Hong Kong-listed biotech companies eligible for Stock Connect, including those listed under Chapter 18A. Its top ten constituents include Innovent Biologics, BeiGene, WuXi Biologics, WuXi AppTec, Akeso, CSPC Pharmaceutical Group, Sino Biopharmaceutical, Hansoh Pharma, 3SBio, and Kelun-Biotech, offering investors a one-stop tool for exposure to the Hong Kong biotech sector.
Read source